Clinical outcome in prostate cancer treated with magnetic resonance imaging-guided high-dose-rate brachytherapy combined with external beam radiotherapy

Figures & data

Table 1. Disease control: actuarial and crude rates for all patients.

	Actuarial rates, %
	5 years	7 years	Crude, %
bRFS	97	89	92
LRFS	100	100	98
DMFS	97	88.3	96
DFS	97	88.3	94
CSS	100	100	100
OS	91	91	92

bRFS: biochemical relapse-free survival (Phoenix definition: PSA nadir +2 ng/ml); LRFS: local relapse-free survival; DMFS: distant metastasis-free survival; DFS: disease-free survival; CSS: cancer-specific survival; OS: overall survival.

Table 2. Frequency of late toxicities for all patients with baseline values.

	Maximum late toxicity, N (%)
	GI		GU
	Baseline	Post-RT	Baseline	Post-RT
Gr.0	49 (94)	38 (73)	34 (66)	24 (46)
Gr.1	3 (6)	12 (23)	9 (17)	9 (17)
Gr.2	0	2 (4)	9 (17)	18 (35)
≥Gr.3	0	0	0	1 (2)

Figure 1. Biochemical relapse-free survival for all patients.

Figure 2. Changes in GI/GU EPIC domain scores from baseline over time. EPIC = Expanded Prostate Cancer Index Composite. Arrows indicate significant (p < .05) changes.